Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03607890

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:13.493151+00:00

Published At

2026-03-16T00:00:00+00:00

Record Updated At

2026-03-16

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy", "MSI-H Tumors"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-03-16"

protocolSection.identificationModule.nctId

"NCT03607890"

protocolSection.identificationModule.officialTitle

"Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy (protocolSection.conditionsModule.conditions)
• MSI-H Tumors (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.